Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients

被引:29
|
作者
Lang, H
Schlitt, HJ
Schmidt, H
Flemming, P
Nashan, B
Scheumann, GFW
Oldhafer, KJ
Manns, MP
Raab, R
机构
[1] Univ Essen Gesamthsch Klinikum, Klin & Poliklin Allgemein & Transplantat Chirurg, D-45122 Essen, Germany
[2] Med Hsch Hannover, Abdominal & Transplantat Chirurg Klin, D-30625 Hannover, Germany
[3] Med Hsch Hannover, Gastroenterol & Hepatol Abt, D-30625 Hannover, Germany
[4] Med Hsch Hannover, Abt Pathol, D-30625 Hannover, Germany
关键词
liver transplantation; neuroendocrine pancreatic tumors; hepatic metastases;
D O I
10.1007/s004230050216
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Metastatic neuroendocrine pancreatic tumors have a poor prognosis. We have studied retrospectively the efficacy of liver transplantation as ultimate therapy of otherwise untreatable symptomatic neuroendocrine hepatic metastases originating in the pancreas. Methods: We reviewed our experience of liver transplantation (LTx) for hepatic metastases of neuroendocrine pancreatic tumors in ten patients. The indication for liver grafting was seen in cases of irresectable metastases and when patients were suffering from otherwise untreatable tumor-associated symptoms due to massive hormonal release or large intra-abdominal turner bulk. Results: In four patients, the primary tumors had been removed before LTx, in five patients simultaneously with LTx and in one case 46 months after grafting. There was no operative mortality. After hepatectomy and LTx, all patients had complete relief of symptoms and all preoperatively increased hormonal levels returned to normal. In nine of ten patients, the transplant procedure had the potential for cure, whereas, in one patient, the primary tumor had remained in situ at LTx and was removed 46 months later by an R2-resection. At present, nine patients are alive with a median follow-up of 33 months (range 13.5 months to 117 months). The one patient in whom the primary tumor was removed after transplantation died due to massive intra-abdominal tumor spread 68 months after LTx. Currently, two patients are without evidence of disease, but one of them after re-operation because of lymph-node metastases 8 months after transplantation. The longest disease-free survival is now more than 7 years. In seven of nine patients, tumor recurred between 1.5 months and 48 months after transplantation. Conclusions: Patients with otherwise untreatable symptomatic neuroendocrine hepatic metastases of pancreatic origin may benefit from total hepatectomy and liver transplantation with regard to symptomatic relief and long-term survival, despite frequent recurrence of disease. In some patients, liver transplantation may even offer the chance for cure.
引用
收藏
页码:370 / 377
页数:8
相关论文
共 50 条
  • [41] Surgical Resection for Metastatic Tumors in the Pancreas: A Single-Center Experience and Systematic Review
    Huang, Qiuyi
    Zhou, Haiyang
    Liu, Chen
    Jin, Kaizhou
    Fan, Kun
    Cheng, He
    Fan, Zhiyao
    Yang, Chao
    Liu, Liang
    Long, Jiang
    Xu, Jin
    Ni, Quanxing
    Hu, Zhiqian
    Yu, Xianjun
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (06) : 1649 - 1656
  • [42] Belatacept in Pancreas Transplantation: Single Center Experience
    Christensen, R.
    Pierce, D.
    Tang, I.
    Campara, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S1048 - S1049
  • [43] Single-Center Experience with Pancreas Transplantation
    Park, J. B.
    Kim, Y. H.
    Song, K. B.
    Chung, Y. S.
    Jang, H. J.
    Park, J. -Y.
    Kim, S. -C.
    Han, D. J.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (04) : 925 - 928
  • [44] Surgical Resection for Metastatic Tumors in the Pancreas: A Single-Center Experience and Systematic Review
    Qiuyi Huang
    Haiyang Zhou
    Chen Liu
    Kaizhou Jin
    Kun Fan
    He Cheng
    Zhiyao Fan
    Chao Yang
    Liang Liu
    Jiang Long
    Jin Xu
    Quanxing Ni
    Zhiqian Hu
    Xianjun Yu
    Annals of Surgical Oncology, 2019, 26 : 1649 - 1656
  • [45] Liver Transplant for Metastatic Neuroendocrine Tumors: A Single-Center Report of 15 Cases
    Moradi, Ali Mohammad
    Entezari, Majid
    Safarpour, Mohammad Mostafa
    Meshksar, Aidin
    Muhammad, Shah
    Dehghani, Masoud
    Hosseini, Seyyed Ali Malek
    Nikeghbalian, Saman
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2021, 19 (06) : 588 - 591
  • [46] Experience with 177Lu-Dotatate in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors at a Single Urban Cancer Center
    Kieft, A. L.
    Ibrahim, Y.
    Dyson, G.
    Baran, G.
    Azmi, A.
    Al Hallak, M. N.
    Shields, A. F.
    Vaishampayan, N. G.
    Philip, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E307 - E308
  • [47] Outcomes and Safety of Living Donor Hepatectomy for Liver Transplantation: A Single-Center Experience
    Kozan, Ramazan
    Sozen, Hakan
    Sar, Sinan
    Gurkan, Odul Egritas
    Akkan, Koray
    Ozturk, Hakan
    Moral, Kenan
    Cindoruk, Mehmet
    Ilgit, Erhan
    Dalgic, Buket
    Dalgic, Aydin
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2024, 26 (01)
  • [48] LONG TERM SURVIVAL OF PATIENTS WITH METASTATIC NEUROENDOCRINE TUMORS AFTER LIVER TRANSPLANTATION AND LIVER RESECTION
    Bauschke, A.
    Altendorf-Hofmann, A.
    Settmacher, U.
    TRANSPLANT INTERNATIONAL, 2021, 34 : 17 - 17
  • [49] Neuroendocrine tumors: Ten years of experience in a Mexican oncology reference center
    Rey Torres-Cisneros, Eduardo
    Burguete-Torres, Alan
    Buenaventura Cisneros, Sergio
    Renata Bruni-Guerrero, Carla
    Otilia Wimer-Castillo, Blanca
    Hernandez-Barajas, David
    Vidal-Gutierrez, Oscar
    Eduardo Salazar-Mejia, Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [50] Liver transplantation for patients with metabolic liver diseases: A single center experience
    Graziadei, Ivo W.
    Winder, Thomas
    Zoller, Heinz
    Kern, Michaela
    Mark, Walter
    Margreiter, Raimund
    Vogel, Wolfgang
    GASTROENTEROLOGY, 2006, 130 (04) : A789 - A789